Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-25
2006-04-25
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S802000, C514S834000, C530S350000, C530S380000
Reexamination Certificate
active
07033994
ABSTRACT:
The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet count or platelet dysfunction, said composition comprising a hemostatic effective amount of Factor VIII and/or von Willebrand Factor. Also provided is a method for treating said bleeding, comprising administering a hemostatic effective amount of Factor VIII and/or von Willebrand Factor to patients suffering from bleeding disorders caused by platelet disorders.
REFERENCES:
patent: 4994438 (1991-02-01), Rubinstein
patent: 5180583 (1993-01-01), Hedner
patent: 5252710 (1993-10-01), Dazey et al.
patent: 5618789 (1997-04-01), Capon et al.
patent: 5760183 (1998-06-01), Dazey et al.
patent: 774261 (1997-05-01), None
patent: EP 0 225 160 (1987-06-01), None
patent: EP 0 469 985 (1992-02-01), None
patent: 98/53848 (1998-12-01), None
Dickneite et al. Reduction of r-hirudin induced bleeding in pigs by the administration of von Willebrand factor. (1996) Platelets, vol. 7, pp. 283-290.
Furlan et al. Von Willebrand Factor in Thrombotic Thrombocytopenic Purpura. (1999) Thromb. Haemost. vol. 82, No. 2, pp. 592 600.
English Translation of Schwarz et al. EP 0 774 261.
Schwarz et al. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. (1998) Haemophilia, vol. 4, (Supp. 3) pp. 53-62.
J. Nishimura, Progress of Medicine, vol. 184, pp. 448-452, 1998.
Y. Kurata, Sogo Rinsho, vol. 47, pp. 2742-2748, 1998.
Ministry of Health and Welfare, Pharmaceutical Affairs Bureau; the Japanese Red Cross Society: As to proper use of platelet preparations.
P.J. Fay et al.; J. Biol. Chem., vol. 226, No. 4, pp. 2172-2177, 1991.
D. Eaton et al.; Biochemistry, vol. 25, pp. 505-512, 1986.
Z.M. Ruggeri et al.; J. Clin. Invest. vol. 99, No. 4, pp. 559-564, 1997.
F. Rotblat et al., Biochemistry, vol. 24, pp. 4294-4300, 1985.
H. J. Weiss et al.; Science, vol. 182, pp. 1149-1151, 1973.
C. A. Fulcher et al.; Proc. Natl. Acad. Sci. USA, vol. 79, pp. 1648-1652, 1982.
D. J. Kuter et al.; Blood, vol. 85, No. 10, pp. 2720-2730, 1995.
Mauz-Koerhølz et al., Arch Dis Child, vol. 78, pp. 257-260 (1998).
Araki Tatsuya
Nakagaki Tomohiro
Nakatomi Yasushi
Teshima Kaori
Tomokiyo Kazuhiko
Juridical Foundation the Chemo-Sero-Therapeutic Research Institu
Schnizer Holly
Wax Robert A.
LandOfFree
Medicinal compositions for preventing and treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal compositions for preventing and treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal compositions for preventing and treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3565617